Free Trial

Hercules Capital (HTGC) Competitors

+0.04 (+0.19%)
(As of 11:24 AM ET)


Should you be buying Hercules Capital stock or one of its competitors? The main competitors of Hercules Capital include iShares Biotechnology ETF (IBB), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Goldman Sachs BDC (GSBD), Tri-Continental (TY), Royce Value Trust (RVT), The Gabelli Equity Trust (GAB), and SRH Total Return Fund (STEW). These companies are all part of the "investment offices, not elsewhere classified" industry.

Hercules Capital vs.

iShares Biotechnology ETF (NASDAQ:IBB) and Hercules Capital (NYSE:HTGC) are both mid-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Hercules Capital has a consensus target price of $18.63, indicating a potential downside of 13.07%. Given Hercules Capital's stronger consensus rating and higher possible upside, analysts plainly believe iShares Biotechnology ETF is more favorable than Hercules Capital.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iShares Biotechnology ETF
0 Sell rating(s)
8 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
Hercules Capital
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)

iShares Biotechnology ETF pays an annual dividend of $0.40 per share and has a dividend yield of 0.3%. Hercules Capital pays an annual dividend of $1.60 per share and has a dividend yield of 7.5%. Hercules Capital pays out 72.7% of its earnings in the form of a dividend.

In the previous week, Hercules Capital had 3 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 6 mentions for Hercules Capital and 3 mentions for iShares Biotechnology ETF. Hercules Capital's average media sentiment score of 0.60 beat iShares Biotechnology ETF's score of 0.37 indicating that iShares Biotechnology ETF is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iShares Biotechnology ETF
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Hercules Capital
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Hercules Capital has higher revenue and earnings than iShares Biotechnology ETF.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iShares Biotechnology ETFN/AN/AN/AN/AN/A
Hercules Capital$460.67M7.54$337.48M$2.209.74

Hercules Capital has a net margin of 69.98% compared to Hercules Capital's net margin of 0.00%. iShares Biotechnology ETF's return on equity of 18.35% beat Hercules Capital's return on equity.

Company Net Margins Return on Equity Return on Assets
iShares Biotechnology ETFN/A N/A N/A
Hercules Capital 69.98%18.35%9.29%

iShares Biotechnology ETF has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Hercules Capital has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Hercules Capital received 305 more outperform votes than iShares Biotechnology ETF when rated by MarketBeat users. However, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 64.27% of users gave Hercules Capital an outperform vote.

iShares Biotechnology ETFOutperform Votes
Underperform Votes
Hercules CapitalOutperform Votes
Underperform Votes

62.5% of iShares Biotechnology ETF shares are held by institutional investors. Comparatively, 19.7% of Hercules Capital shares are held by institutional investors. 1.9% of Hercules Capital shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Hercules Capital beats iShares Biotechnology ETF on 9 of the 16 factors compared between the two stocks.

Get Hercules Capital News Delivered to You Automatically

Sign up to receive the latest news and ratings for HTGC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HTGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HTGC vs. The Competition

MetricHercules CapitalInvestment offices IndustryFinance SectorNYSE Exchange
Market Cap$3.47B$7.96B$9.93B$18.71B
Dividend Yield7.54%6.10%10.10%3.49%
P/E Ratio9.740.4457.2225.72
Price / Sales7.5420.37255.6717.03
Price / Cash10.317.9528.7916.26
Price / Book1.801.012.665.19
Net Income$337.48M$73.96M$1.01B$971.37M
7 Day Performance1.73%1.42%4.76%5.95%
1 Month Performance9.42%3.22%6.46%7.05%
1 Year Performance32.33%6.23%12.29%10.82%

Hercules Capital Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
iShares Biotechnology ETF
0 of 5 stars
0.00 / 5 stars
DNP Select Income Fund
0 of 5 stars
0.00 / 5 stars
N/A-15.8%$2.96BN/A0.00N/AShort Interest ↑
Adams Diversified Equity Fund
0 of 5 stars
0.00 / 5 stars
N/A+31.4%$2.77BN/A0.00N/ANews Coverage
PIMCO Corporate & Income Opportunity Fund
0 of 5 stars
0.00 / 5 stars
Liberty All-Star Equity Fund
0 of 5 stars
0.00 / 5 stars
N/A+7.1%$1.88BN/A0.00N/ANews Coverage
Goldman Sachs BDC
0.3355 of 5 stars
0.34 / 5 stars
+9.1%$1.74B$224.55M8.12N/AShort Interest ↑
0 of 5 stars
0.00 / 5 stars
Royce Value Trust
0 of 5 stars
0.00 / 5 stars
N/A+13.1%$1.61BN/A0.00147,000News Coverage
Gap Up
The Gabelli Equity Trust
0 of 5 stars
0.00 / 5 stars
N/A-4.5%$1.59BN/A0.00N/APositive News
SRH Total Return Fund
0 of 5 stars
0.00 / 5 stars
N/A+14.4%$1.43BN/A0.00N/APositive News

Related Companies and Tools

This page (NYSE:HTGC) was last updated on 7/17/2024 by Staff

From Our Partners